|
SRBD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.5122573172639E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.26559873692145E-11 |
| Normal-vs-Stage2 |
4.724500E-03 |
| Normal-vs-Stage3 |
4.69846384021366E-13 |
| Normal-vs-Stage4 |
1.62503344114384E-12 |
| Stage1-vs-Stage2 |
7.970300E-02 |
| Stage1-vs-Stage3 |
4.184000E-02 |
| Stage1-vs-Stage4 |
2.441400E-04 |
| Stage2-vs-Stage3 |
7.138600E-03 |
| Stage2-vs-Stage4 |
2.845200E-04 |
| Stage3-vs-Stage4 |
1.074600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.88737914186277E-14 |
| Normal-vs-AfricanAmerican |
2.203100E-03 |
| Normal-vs-Asian |
4.01512156855688E-12 |
| Caucasian-vs-AfricanAmerican |
3.238400E-01 |
| Caucasian-vs-Asian |
2.670800E-01 |
| AfricanAmerican-vs-Asian |
1.876990E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.38959954654183E-10 |
| Normal-vs-Female |
2.40663045047995E-12 |
| Male-vs-Female |
8.553800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.18043419062542E-12 |
| Normal-vs-Age(41-60Yrs) |
2.56539234300135E-12 |
| Normal-vs-Age(61-80Yrs) |
1.19620002791976E-09 |
| Normal-vs-Age(81-100Yrs) |
3.884700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.103000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.656400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.035400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.441200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.457600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.887800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.002400E-02 |
| Classical-VS-Follicular |
1.756030E-02 |
| Classical-VS-Other |
9.509600E-01 |
| Classical-VS-Normal |
1.70208291905283E-12 |
| Tall-VS-Follicular |
5.99139999999387E-05 |
| Tall-VS-Other |
4.786600E-01 |
| Tall-VS-Normal |
2.55384602354525E-12 |
| Follicular-VS-Other |
4.276600E-01 |
| Follicular-VS-Normal |
1.179020E-04 |
| Other-VS-Normal |
8.263600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.32549551732109E-11 |
| Normal-vs-N1 |
4.55191440096314E-15 |
| N0-vs-N1 |
7.223500E-04 |
|
|
